NCT01444118 - A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients | Biotech Hunter

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL

Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)

Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.

Trial Locations (1)

Unknown

Aberdeen Royal Infirmary, Aberdeen